RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cancer Research

• Publication date

  2008-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-08-0413PMID 18519677PMCID PMC4341915
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prostaglandin E2 Receptor EP1 Transactivates EGFR/MET Receptor Tyrosine Kinases and Enhances Invasiveness in Human Hepatocellular Carcinoma Cells

  2015cited by this paper
• Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt.

  2015cited by this paper
• Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells

  2006cited by this paper
• Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis.

  2006influential reference
• Epidermal growth factor receptor (EGFR) signaling in cancer.

  2006cited by this paper
• Two targets, one drug for new EGFR inhibitors.

  2006cited by this paper
• AP-2α: a regulator of EGF receptor signaling and proliferation in skin epidermis

  2006cited by this paper
• Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells.

  2005cited by this paper
• Cyclooxygenase-2-derived Prostaglandin E2 Promotes Human Cholangiocarcinoma Cell Growth and Invasion through EP1 Receptor-mediated Activation of the Epidermal Growth Factor Receptor and Akt*

  2005cited by this paper
• Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788

  2005cited by this paper
• How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy.

  2004cited by this paper
• Src Homology 3 Binding Sites in the P2Y2 Nucleotide Receptor Interact with Src and Regulate Activities of Src, Proline-rich Tyrosine Kinase 2, and Growth Factor Receptors*

  2004cited by this paper
• Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid Cancer

  2004cited by this paper
• Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study.

  2003cited by this paper
• Targeting HER1/EGFR: a molecular approach to cancer therapy.

  2003cited by this paper
• Pathology of small cell carcinoma of the lung.

  2003cited by this paper
• RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase

  2003cited by this paper
• Microsomal Prostaglandin E2 Synthase-1 Is Induced by Conditional Expression of RET/PTC in Thyroid PCCL3 Cells through the Activation of the MEK-ERK Pathway*

  2003cited by this paper
• Processing of gene expression data generated by quantitative real-time RT-PCR.

  2002cited by this paper
• Mechanisms of the regulation of EGF receptor gene expression by calcitriol and parathyroid hormone in UMR 106-01 cells.

  2002cited by this paper
• Molecular Mechanisms of RET Activation in Human Cancer

  2002cited by this paper
• The GDNF family: Signalling, biological functions and therapeutic value

  2002cited by this paper
• ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR‐positive cancer cell lines with or without erbB2 overexpression

  2001cited by this paper
• Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival.

  2001cited by this paper
• Receptor Heterodimerization: Essential Mechanism for Platelet-Derived Growth Factor-Induced Epidermal Growth Factor Receptor Transactivation

  2001cited by this paper
• Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.

  2000cited by this paper
• Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells.

  2000cited by this paper
• Conditional apoptosis induced by oncogenic ras in thyroid cells.

  2000cited by this paper
• Transactivation of the EGF Receptor Mediates IGF-1-stimulated Shc Phosphorylation and ERK1/2 Activation in COS-7 Cells*

  2000cited by this paper
• Co-overexpression of p53 protein and epidermal growth factor receptor in human papillary thyroid carcinomas correlated with lymph node metastasis, tumor size and clinicopathologic stage.

  1999cited by this paper
• EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF

  1999cited by this paper
• Shc and Enigma Are Both Required for Mitogenic Signaling by Ret/ptc2

  1998cited by this paper
• Leucine Zipper-mediated Dimerization Is Essential for the PTC1 Oncogenic Activity*

  1997cited by this paper
• Cellular functions regulated by Src family kinases.

  1997cited by this paper
• Gbetagamma subunits mediate Src-dependent phosphorylation of the epidermal growth factor receptor. A scaffold for G protein-coupled receptor-mediated Ras activation.

  1997cited by this paper
• Growth inhibition of human papillary thyroid carcinoma cells and multicellular spheroids by anti-EGF-receptor antibody.

  1997cited by this paper
• Tyrosines outside the Kinase Core and Dimerization Are Required for the Mitogenic Activity of RET/ptc2 (*)

  1995cited by this paper
• Epidermal growth factor-related peptides and their receptors in human malignancies.

  1995cited by this paper
• Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma.

  1994cited by this paper
• Expression of epidermal growth factor, transforming growth factor-alpha and epidermal growth factor receptor in thyroid tumors.

  1992cited by this paper
• Abnormalities of the EGF receptor system in human thyroid neoplasia

  1991cited by this paper
• H-ras protooncogene mutations in human thyroid neoplasms.

  1990cited by this paper
• Identification and characterization of a regulated promoter element in the epidermal growth factor receptor gene.

  1990cited by this paper
• Co‐expression of the genes encoding transforming growth factor‐α and its receptor in papillary carcinomas of the thyroid

  1990cited by this paper
• Thyrotropin modulates EGF receptor function in porcine thyroid follicle cells.

  1985cited by this paper
• Epidermal growth factor receptors in normal and neoplastic thyroid tissue.

  1985cited by this paper

• Anti-tumour effects of combined lenvatinib and EGFR Inhibition in advanced differentiated thyroid cancer cells

  2026cites this paper
• Comparison of 46 Cytokines in Peripheral Blood Between Patients with Papillary Thyroid Cancer and Healthy Individuals with AI-Driven Analysis to Distinguish Between the Two Groups

  2025cites this paper
• Targeting endothelial growth factor receptor in thyroid cancer: current concepts and future directions

  2025cites this paper
• Novel Detection Method for Circulating EGFR Tumor DNA Using Gravitationally Condensed Gold Nanoparticles and Catalytic Walker DNA

  2022cites this paper
• Anti-Müllerian hormone: A function beyond the Müllerian structures.

  2021cites this paper
• Expression of Transforming Growth Factor Alpha and Their Receptor (EGFR) in Thyroid Carcinoma and Benign Patients

  2020cites this paper
• Proteomics in thyroid cancer and other thyroid-related diseases: A review of the literature.

  2020cites this paper
• Novel treatments for anaplastic thyroid carcinoma.

  2020cites this paper
• Molecular targets of tyrosine kinase inhibitors in thyroid cancer.

  2020cites this paper
• Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes

  2019cites this paper
• Molecular mechanisms and pathobiology of oncogenic fusion transcripts in epithelial tumors

  2019cites this paper
• EGFR and CXCR1 expression in thyroid carcinoma in Qassim Region-Saudi Arabia: Correlation with clinicopathological parameters.

  2019cites this paper
• Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes

  2019cites this paper
• Recent advances in precision medicine for the treatment of anaplastic thyroid cancer

  2019cites this paper
• Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes

  2018cites this paper
• Molecular markers in well-differentiated thyroid cancer

  2018cites this paper
• EGFR mediates activation of RET in lung adenocarcinoma with neuroendocrine differentiation characterized by ASCL1 expression

  2017cites this paper
• Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases

  2017cites this paper
• Loss of sorting nexin 5 stabilizes internalized growth factor receptors to promote thyroid cancer progression

  2017cites this paper
• Expression of Transforming Growth Factorα and Epidermal Growth Factor Receptor in Thyroid Carcinoma

  2017cites this paper
• EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases.

  2017cites this paper
• Novel treatment options for anaplastic thyroid cancer

  2017cites this paper
• Targeted Therapy for Medullary Thyroid Cancer: A Review

  2017cites this paper
• High-Throughput Bioinformatics Approaches to Understand Gene Expression Regulation in Head and Neck Tumors.

  2016cites this paper
• The Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor Family

  2016influential citation
• Expression of Tenascin C, EGFR, E-Cadherin, and TTF-1 in Medullary Thyroid Carcinoma and the Correlation with RET Mutation Status

  2016cites this paper
• Systemic treatment and management approaches for medullary thyroid cancer.

  2016cites this paper
• The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer

  2016cites this paper
• In vitro transforming potential, intracellular signaling properties and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu and Arg886Trp.

  2016cites this paper
• Selective use of vandetanib in the treatment of thyroid cancer

  2015cites this paper
• Expression of the estrogen receptor α, progesterone receptor and epidermal growth factor receptor in papillary thyroid carcinoma tissues.

  2015cites this paper
• Molecular Targeted Therapies of Aggressive Thyroid Cancer

  2015influential citation
• Genomic binding and regulation of gene expression by the thyroid carcinoma-associated PAX8-PPARG fusion protein

  2015cites this paper
• Overexpression of EphB4, EphrinB2, and epidermal growth factor receptor in papillary thyroid carcinoma: A pilot study

  2015cites this paper
• Tyrosine kinase inhibitors for the therapy of anaplastic thyroid cancer

  2015cites this paper
• The RET oncogene in papillary thyroid carcinoma

  2015cites this paper
• New Therapies for Dedifferentiated Papillary Thyroid Cancer

  2015cites this paper
• HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo

  2015cites this paper
• Personalization of Targeted Therapy in Advanced Thyroid Cancer

  2014influential citation
• Structural modeling of regulation in alpha-actinin/F-actin interactions

  2014cites this paper
• Genetics and epigenetics of sporadic thyroid cancer.

  2014cites this paper
• Selective inhibition of RET mediated cell proliferation in vitro by the kinase inhibitor SPP86

  2014influential citation
• Update on medullary thyroid cancer.

  2014cites this paper
• Mullerian inhibiting substance expression in papillary thyroid cancer.

  2013cites this paper
• Studies of targeted treatment in RET mutant thyroid cancers

  2013cites this paper
• Cellular Signaling Pathway Alterations and Potential Targeted Therapies for Medullary Thyroid Carcinoma

  2013cites this paper
• Thyroid cancer in children and adolescents

  2013cites this paper
• New Diagnostic and Therapeutic Tools for Thyroid Cancer

  2013influential citation
• Vandetanib for the Treatment of Thyroid Cancer

  2012cites this paper
• Inhibition of RET activated pathways: novel strategies for therapeutic intervention in human cancers.

  2012cites this paper
• Pediatric thyroid cancer.

  2012cites this paper
• KIF5B-RET fusions in lung adenocarcinoma

  2012cites this paper
• Novel molecular targeted therapies for refractory thyroid cancer

  2012influential citation
• Intracellular Signal Transduction and Modification of the Tumor Microenvironment Induced by RET/PTCs in Papillary Thyroid Carcinoma

  2012cites this paper
• RET TKI: Potential Role in Thyroid Cancers

  2012cites this paper
• Multikinase inhibitors in thyroid cancer.

  2012cites this paper
• In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.

  2011cites this paper
• How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer

  2011cites this paper
• Medullary Thyroid Carcinoma: Molecular Signaling Pathways and Emerging Therapies

  2011cites this paper
• Regulation of epidermal growth factor receptor signalling by inducible feedback inhibitors

  2011cites this paper
• Synthesis and in vitro EGFR (ErbB1) tyrosine kinase inhibitory activity of 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines.

  2011cites this paper
• Response to Sorafenib at a Low Dose in Patients with Radioiodine-Refractory Pulmonary Metastases from Papillary Thyroid Carcinoma

  2011cites this paper
• Does the Epidermal Growth Factor Receptor Play a Role in the Progression of Thyroid Cancer?

  2011cites this paper
• Quantitative analysis of the expression of TGF-alpha and EGFR in papillary thyroid carcinoma: clinicopathological relevance

  2011influential citation
• Management of Thyroid and Parathyroid Cancers

  2011cites this paper
• The Epidermal Growth Factor Receptor in Normal and Neoplastic Epithelia

  2011cites this paper
• Signal transduction in the human thyrocyte and its perversion in thyroid tumors.

  2010cites this paper
• The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.

  2010cites this paper
• The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors.

  2010cites this paper
• Tyrosine kinase inhibitors.

  2010cites this paper
• Sunitinib induces PTEN expression and inhibits PDGFR signaling and migration of medulloblastoma cells

  2010cites this paper
• Integrated Ligand-Receptor Bioinformatic and In Vitro Functional Analysis Identifies Active TGFA/EGFR Signaling Loop in Papillary Thyroid Carcinomas

  2010cites this paper
• [Usefulness of the immunohistochemical analysis of several molecular markers in the characterization of papillary thyroid carcinoma with initial lymph node metastasis].

  2010cites this paper
• Paracrine regulation of pancreatic cancer cell invasion by peripheral nerves.

  2010cites this paper
• Current review of small molecule Ret kinase inhibitors.

  2010cites this paper
• The tyrosine kinase inhibitor ZD 6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells

  2010cites this paper
• Multikinase inhibitors in thyroid cancer.

  2010cites this paper
• Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis.

  2010cites this paper
• 1H,13C and 19F NMR data of N‐substituted 6‐(4‐methoxyphenyl)‐7H‐pyrrolo[2,3‐d]pyrimidin‐4‐amines in DMSO‐d6

  2010cites this paper
• Angiotensin II-induced activation of c-Ret signaling is critical in ureteric bud branching morphogenesis.

  2010cites this paper
• Structure-Function Studies of GDNF Family Ligand-RET signalling

  2009cites this paper
• Targeted therapies in thyroid cancer

  2009cites this paper
• Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma

  2009cites this paper
• Targeting RET for thyroid cancer therapy.

  2009cites this paper
• The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation.

  2009cites this paper
• How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer

  2009cites this paper
• Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets.

  2009cites this paper
• Medullary Thyroid Cancer: Molecular Biology and Novel Molecular Therapies

  2009cites this paper
• New targets and therapeutic approaches for endocrine malignancies.

  2009cites this paper
• Receptor tyrosine kinase inhibitors in thyroid cancer.

  2008cites this paper
• Molecular targets in medullary thyroid carcinoma

  2008cites this paper
• New agents in the treatment for malignancies of the salivary and thyroid glands.

  2008cites this paper